January 2024 - Page 6 of 32

IDWeek Commentary | Dr. Mei Zeng: Racing Against Time! Developing a Predictive Model for Early Identification of Severe Infections in Newborns

By Mourabit Halima 2024.01.23

Half of all global child deaths under the age of 5 are caused by infections, and half of all sepsis patients worldwide are children, especially newborns. These alarming statistics highlight the significant challenge of infection treatment in pediatric clinical practice. At the recent IDWeek 2023 in the United States, a predictive model for severe infection in infants under 90 days of age, based on clinical data and inflammatory biomarkers, was reported. This predictive model may aid in the early identification of newborns at high risk of severe infection, allowing timely clinical intervention to reduce the risk of disease progression. Dr. Mei Zeng from the Children's Hospital of Fudan University/National Children's Medical Center provides an introduction and commentary on this research.

Multiple HIV Research Achievements by Dr. Yaokai Chen’s Team from Chongqing Public Health Medical Center Was Selected for the 2023 IDWeek

By Mourabit Halima 2024.01.23

Editor's Note: The IDWeek in the United States is one of the largest infectious disease academic conferences globally, often referred to as the "Oscars" of the infectious disease field. Numerous cutting-edge research findings would be shared and discussed at this highly anticipated academic event. During the recent 2023 IDWeek, Dr. Yaokai Chen's team from Chongqing Public Health Medical Center had four HIV-related research findings selected for the conference. One of these was presented as a Rapid-Fire Poster, while the other three were included in poster presentations.

IDWeek Commentary | Dr. Hongmei Xu: CMV PCR Agreement between Blood and Dried Blood Spots in Infants with Congenital Cytomegalovirus Infection

By Mourabit Halima 2024.01.23

Infants can be infected with congenital cytomegalovirus (CMV) through vertical mother-to-child transmission, and CMV infection screening is required for some newborns with specific indications. Polymerase chain reaction (PCR) is a commonly used clinical method for qualitative or quantitative diagnosis of CMV, and it can test specimens such as urine, plasma, and dried blood spots, each with its own advantages and disadvantages. A recent study evaluating the consistency of plasma PCR and dried blood spot PCR for CMV infection diagnosis was presented at the 2023 IDWeek. Dr. Hongmei Xu from Children's Hospital of Chongqing Medical University introduces and comments on this study.

Dr. Lungen Lu: Intermittent Fasting vs. Standard Caloric Restriction – A Better Approach to Improving NAFLD Fibrosis and Metabolism

By Mourabit Halima 2024.01.23

Dietary adjustments currently stand as the primary treatment for Non-Alcoholic Fatty Liver Disease (NAFLD). At the 58th European Association for the Study of the Liver (EASL) Annual Meeting (EASL 2023), Deepankshi Aggarwal from India presented their team's latest findings in an oral presentation. They discussed how time-restricted intermittent fasting may be superior to standard caloric restriction in improving the metabolic status and liver fibrosis of NAFLD patients. Dr. Lungen Lu's team from the First People's Hospital of Shanghai Jiao Tong University School of Medicine offered insights into this research.

Dr.Jinshui Pan’s Team: Revealing the Heavy Tumor Burden Caused by Metabolic Risk Factors Worldwide (1990-2019)

By Mourabit Halima 2024.01.23

Non-alcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver disease, often coexisting with various metabolic risk factors, which are significantly associated with the risk of various tumors. Dr.Jinshui Pan and ProfessoDr. Shang Weng from the Liver Disease Center of Fujian Medical University Affiliated First Hospital, along with Dr. Meizhu Hong from Mengchao Hepatobiliary Hospital, conducted an analysis and assessment of the global burden of metabolic-related tumors from 1990 to 2019 based on the Global Burden of Disease (GBD) database for 2019. The research paper was published in the journal Med, under Cell Press, with an impact factor of 17 in 2023. Additionally, these findings were selected for presentation at the 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the EASL Congress 2023.

Dr.Wai-Kay Seto’s team Multiple Studies on Hepatic Diseases Management with New Hepatitis B Drugs Fatty Liver Monitoring and Liver Cancer Risk Factors

By Mourabit Halima 2024.01.23

The 58th Annual Meeting of the European Association for the Study of the Liver (EASL2023) and the EASL Congress 2023 have come to a close. During this conference, Dr. Wai-Kay Seto and his research team from The University of Hong Kong Shenzhen Hospital/ The University of Hong Kong presented several studies. Hepatology Digest had the privilege of inviting Professor Wai-Kay Seto to introduce three of the significant studies: the impact of blood sugar control on reducing the risk of digestive tract tumors in diabetes patients [1], preliminary safety and antiviral activity analysis of the Chinese-developed siRNA new drug RBD1016 in the Chinese chronic hepatitis B population [2], and a new technique for portable assessment of fatty liver [3]. The details of these studies are as follows:

Dr. Wenshi Wang’s Team: Three Latest Research Findings on Hepatitis D and Hepatitis E Included in Conference Exchange

By Mourabit Halima 2024.01.22

Hepatitis D (HDV) is a viral hepatitis caused by hepatitis D virus (HDV) infection, often occurring as a co-infection or superinfection with hepatitis B virus (HBV). Approximately 90% of chronic hepatitis B patients who become co-infected with HDV develop chronic hepatitis, increasing the risk of adverse outcomes such as liver failure, cirrhosis, and liver cancer. Due to the historical underestimation of HDV prevalence and disease burden, it has not received the attention it deserves. Hepatitis E virus (HEV) infection is a major cause of acute hepatitis globally, with no specific antiviral drugs available.

ESMO Expert Commentary | Roxadustat Non-inferior to Standard Treatment, Poised to Transform Clinical Practice in Chemotherapy-Induced Anemia

By Mourabit Halima 2024.01.22

Platinum-based, taxane, anthracycline, and other chemotherapy drugs are commonly used in the treatment of various cancers such as breast and lung cancer. However, these chemotherapy agents, known marrow suppressors, can lead to chemotherapy-induced anemia (CIA), resulting in a decline in functional capacity and diminished quality of life for patients. This year's ESMO conference revealed the results of a Phase III clinical study on roxadustat in treating CIA in patients with non-myeloid malignancies, offering a more convenient treatment option for CIA patients. "Oncology Frontier" is honored to invite Professor Yongmei Yin from Jiangsu Provincial People's Hospital and Professor Jian Zhang from Fudan University Cancer Hospital to share insights into the current challenges in CIA treatment and the significance of this study for CIA patients.

Dr. Chao Wu: Current State and Prospects of Clinical Cure for Hepatitis B

By Mourabit Halima 2024.01.22

Clinical cure of hepatitis B has been a hot topic in the field of viral hepatitis, and the 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the 2023 EASL Congress unveiled numerous advancements in new drug research. Dr. Chao Wu and his team from the Department of Infectious Diseases at the Affiliated Drum Tower Hospital of Nanjing Medical University have been engaged in both clinical and basic research on viral hepatitis. In the 2023 EASL Congress, their team contributed 14 research findings, with three of them receiving the Young Investigator Awards. Hepatology Digest invited Dr. Chao Wu to discuss the current state of clinical cure for hepatitis B and analyze future prospects, as well as his thoughts on the overall development of liver diseases.

Dr. Yong-an Ye’s Team: Predicting Virological Recurrence in Chronic Hepatitis B with Machine Learning After Entecavir Discontinuation

By Mourabit Halima 2024.01.22

Currently, most chronic hepatitis B (CHB) patients cannot achieve a cure. While guidelines suggest that some CHB patients can discontinue nucleos(t)ide analogs (NAs) after consolidation therapy, virological recurrence remains common. Early virological recurrence typically predicts disease flare-up; however, there are limited biomarkers for assessing the risk of virological recurrence after treatment cessation. Dr. Yong-an Ye 's team at the Dongzhimen Hospital of Beijing University of Chinese Medicine (Chinese Institute of Traditional Chinese Medicine for Liver Diseases) conducted a prospective randomized controlled trial (RCT) and constructed a new predictive model based on serological markers to identify the risk of early virological recurrence in Chinese CHB patients after discontinuing entecavir (ETV). The findings were presented in poster format during the 58th European Association for the Study of the Liver (EASL) International Liver Congress 2023